Preliminary results of capecitabine metronomic chemotherapy in operable triple-negative breast cancer after standard adjuvant therapy : a singlearm phase II study
المؤلفون المشاركون
المصدر
Journal of the Egyptian National Cancer Institute
العدد
المجلد 26، العدد 4 (31 ديسمبر/كانون الأول 2014)، ص ص. 195-202، 8ص.
الناشر
جامعة القاهرة المعهد القومي للأورام
تاريخ النشر
2014-12-31
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الموضوعات
الملخص EN
The aim of this study is to investigate efficacy and toxicity of 1 year of capecitabine metronomic therapy preceded by standard adjuvant chemotherapy in triple-negative breast cancer (TNBC) patients.
Methods : Between June 2010 and February 2012, 19 women with pathologically proven operable TNBC, who had received standard adjuvant chemotherapy before were enrolled.
Patients received 1 year of oral capecitabine metronomic therapy (650 mg / m2, twice every day), after standard adjuvant chemotherapy and radiotherapy if indicated.
The primary endpoints of this study were disease-free survival rates (DFS) and safety profile.
Secondary end point was overall survival (OS).
Results : The maximal follow-up was 46.6 months with a median of 30.1 months ± 11.525 (95 % CI ; 28.5–33.5 months).
The median DFS was 41.7 months ± 2.7 (95 % CI ; 36.5–46.9).
No one developed locoregional recurrence.
The actuarial rate of DFS was 88.8 % and 82.05 % at 2 and 3 years, respectively.
At the time of the analyses, no patients had died and the median OS was not reached.
Treatment-related adverse events were manageable with only 1 patient (5.3 %) suffering from Grade 3 / 4 hand-foot syndrome and another 1 patient (5.3 %) suffering from Grade 3 diarrhea.
No Grade 3 / 4 hematologic toxicity was recorded.
All patients received full doses of capecitabine throughout the study and dose reduction was not required in any of our patients.
Conclusion : One year of capecitabine metronomic therapy preceded by standard adjuvant chemotherapy, is active and well-tolerated in TNBC patients previously treated with standard adjuvant chemotherapy.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Shawqi, Hanan& Jalal, Samar. 2014. Preliminary results of capecitabine metronomic chemotherapy in operable triple-negative breast cancer after standard adjuvant therapy : a singlearm phase II study. Journal of the Egyptian National Cancer Institute،Vol. 26, no. 4, pp.195-202.
https://search.emarefa.net/detail/BIM-428617
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Shawqi, Hanan& Jalal, Samar. Preliminary results of capecitabine metronomic chemotherapy in operable triple-negative breast cancer after standard adjuvant therapy : a singlearm phase II study. Journal of the Egyptian National Cancer Institute Vol. 26, no. 4 ( 2014), pp.195-202.
https://search.emarefa.net/detail/BIM-428617
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Shawqi, Hanan& Jalal, Samar. Preliminary results of capecitabine metronomic chemotherapy in operable triple-negative breast cancer after standard adjuvant therapy : a singlearm phase II study. Journal of the Egyptian National Cancer Institute. 2014. Vol. 26, no. 4, pp.195-202.
https://search.emarefa.net/detail/BIM-428617
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 200-202
رقم السجل
BIM-428617
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر